Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-101 in Adult Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-101 in Adult Healthy Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs ALPN 101 (Primary)
  • Indications Autoimmune disorders; Inflammation
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Nov 2018 Status changed from planning to not yet recruiting.
    • 24 Apr 2017 New trial record
    • 18 Apr 2017 Accoording to a Nivalis Therapeutics media release, company plans to initiate this trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top